Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00053638 | A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy | PHASE3 | COMPLETED | 345 | — | — | Feb 1, 2003 | Oct 1, 2004 | Oct 4, 2010 | 58 | United States |
| Name | Type | Description |
|---|---|---|
| efavirenz | DRUG | - |
| tenofovir | DRUG | - |
| abacavir/lamivudine | DRUG | - |
Inclusion criteria: * Participants must be able to provide informed consent. * Have documented HIV-1 infection. * Have not received more than 14 days of prior treatment with antiretroviral drugs. * Meet laboratory test criteria. * Women of childbearing potential must abstain from sexual intercourse...